Entrada Cost Of Revenue vs Operating Income Analysis
| TRDA Stock | USD 19.89 0.06 0.30% |
Entrada Therapeutics financial indicator trend analysis is much more than just examining Entrada Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Entrada Therapeutics is a good investment. Please check the relationship between Entrada Therapeutics Cost Of Revenue and its Operating Income accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.
Cost Of Revenue vs Operating Income
Cost Of Revenue vs Operating Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Entrada Therapeutics Cost Of Revenue account and Operating Income. At this time, the significance of the direction appears to have very week relationship.
The correlation between Entrada Therapeutics' Cost Of Revenue and Operating Income is 0.27. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Operating Income in the same time period over historical financial statements of Entrada Therapeutics, assuming nothing else is changed. The correlation between historical values of Entrada Therapeutics' Cost Of Revenue and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Entrada Therapeutics are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Cost Of Revenue i.e., Entrada Therapeutics' Cost Of Revenue and Operating Income go up and down completely randomly.
Correlation Coefficient | 0.27 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Cost Of Revenue
Cost of Revenue is found on Entrada Therapeutics income statement and represents the costs associated with goods and services Entrada Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Operating Income
Operating Income is the amount of profit realized from Entrada Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Entrada Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most indicators from Entrada Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Entrada Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.The current year's Enterprise Value is expected to grow to about 569.3 M, whereas Selling General Administrative is forecasted to decline to about 19.2 M.
| 2021 | 2023 | 2024 (projected) | Depreciation And Amortization | 1.1M | 2.8M | 3.0M | Interest Income | 2.6M | 15.2M | 16.0M |
Entrada Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Entrada Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Entrada Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entrada Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entrada Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entrada Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.44 | Revenue Per Share 6.074 | Quarterly Revenue Growth (0.55) | Return On Assets 0.0695 | Return On Equity 0.1642 |
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.